Motor end-plate analysis to diagnose immune-mediated myasthenia gravis in seronegative patients.

Clustered AChR antibody Complement Motor end-plate Myasthenia gravis Seronegative

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 12 2022
Historique:
received: 14 06 2022
revised: 08 11 2022
accepted: 10 11 2022
pubmed: 21 11 2022
medline: 1 12 2022
entrez: 20 11 2022
Statut: ppublish

Résumé

This study aimed to evaluate the diagnostic usefulness of motor end-plate (MEP) analysis along with clustered acetylcholine receptor (AChR) antibody (Ab) assays in patients with myasthenia-like symptoms but negative routine AChR and muscle-specific kinase (MuSK) Ab tests. MEP analysis of muscle biopsies of the biceps brachii was performed in 20 patients to try to differentiate between those with or without immune-mediated myasthenia gravis (MG). Using a quantitative method, complement C3 deposition and AChR densities in MEPs were examined. Independently, cell-based assays were used to detect serum clustered-AChR Abs. Only five of 20 patients had complement deposition at MEPs; four of these patients had reduced AChR densities similar to those in patients with typical AChR Ab positive MG, and distinct from those in the remaining 15 patients. Two of the four serum samples from these patients had clustered-AChR Abs. All complement-positive patients were considered as having immune-mediated MG and improved with appropriate treatments; although one patient presented with MG 3 years later, the remaining patients had other diagnoses during over 10 years of follow-up. These results suggest the usefulness of MEP analysis of muscle biopsies in diagnosing immune-mediated MG in seronegative patients with myasthenia-like symptoms but, due to the invasiveness of the muscle biopsy procedure, clustered AChR Abs should, if possible, be tested first.

Identifiants

pubmed: 36403297
pii: S0022-510X(22)00356-2
doi: 10.1016/j.jns.2022.120494
pii:
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120494

Subventions

Organisme : Medical Research Council
ID : MR/M006824/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Atsushi Nagaoka (A)

Department of Clinical Neuroscience, Unit of Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan. Electronic address: a-naga@nagasaki-u.ac.jp.

Akira Tsujino (A)

Department of Clinical Neuroscience, Unit of Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan. Electronic address: akrtjn@nagasaki-u.ac.jp.

Hirokazu Shiraishi (H)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan.

Tadashi Kanamoto (T)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan.

Tomoaki Shima (T)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan. Electronic address: tomoakishima0915@nagasaki-u.ac.jp.

Shunsuke Yoshimura (S)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan. Electronic address: shun-yoshimura@nagasaki-u.ac.jp.

Teiichiro Miyazaki (T)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan. Electronic address: tmiyazaki@nagasaki-u.ac.jp.

Yohei Tateishi (Y)

Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki City, Japan. Electronic address: ytate@nagasaki-u.ac.jp.

Mitsuhiro Tsujihata (M)

Nagasaki Kita Hospital, Nagasaki City, Japan. Electronic address: kita_m_tsuji@mx22.tiki.ne.jp.

Masakatsu Motomura (M)

Medical Electronic Course, Nagasaki Institute of Applied Science, Nagasaki City, Japan. Electronic address: MOTOMURA_Masakatsu@NiAS.ac.jp.

Susan Maxwell (S)

Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. Electronic address: susan.maxwell@ndcn.ox.ac.uk.

Osamu Higuchi (O)

Department of Neurology, Nagasaki Kawatana Medical Center, Nagasaki, Japan. Electronic address: osmhgc_nkmc@nagasaki-u.ac.jp.

David Beeson (D)

Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. Electronic address: David.beeson@ndcn.ox.ac.uk.

Angela Vincent (A)

Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. Electronic address: angela.vincent@ndcn.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH